News | August 05, 2009

Nile Therapeutics Doses First Patient in Phase 2 Study of Heart Failure Treatment

August 5, 2009 – Nile Therapeutics Inc. said this week it dosed its first patient in a phase 2 clinical study of its lead product, CD-NP, for the treatment of acute heart failure.

The single-blind, placebo-controlled study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function. The study is expected to enroll approximately 30 to 40 patients in the United States, Germany and Israel and will examine up to three doses of CD-NP.

"Currently there is a significant unmet need in acute heart failure for treatments that can both relieve symptoms and also preserve or enhance renal function in these patients," said James Young, MD, George and Linda Kaufman chair and professor, Cleveland Clinic, and the principal investigator on the study. "The potential of CD-NP to meet both of these objectives is a compelling scientific story, and is of particular clinical importance for the approximately two-thirds of heart failure patients with pre-existing renal dysfunction."

Previously reported results of a phase 1b study in chronic heart failure patients showed that CD-NP infusion was associated with an improvement in renal function. Previously reported interim results from the first cohort of a Phase 2a study in patients hospitalized for acute heart failure also showed that CD-NP infusion was associated with clinically meaningful improvements in cardiac filling pressures, which are expected to correlate with improvement in symptoms in acute heart failure.

Nile expects to announce interim results of the study later this year, with results from the full study available in 2010.

For more information: www.nilethera.com

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init